relative to the right of licensed health care providers to freely communicate with patients, colleagues, and the public about medical information, emerging therapies, and treatment options.
HB 1117 creates a new chapter in New Hampshire law, titled the “Health Care Provider Free Speech and Innovation Act,” to protect licensed health care providers when they communicate about medical research, emerging therapies, experimental treatments, innovative therapies, and off-label medication uses. The bill states that providers may speak with patients, other providers, and the public about these topics without being subject to disciplinary action, professional sanction, or civil or criminal liability, so long as the communication is made in good faith and is not knowingly false or misleading.
The bill also protects providers who recommend, prescribe, or use non-standard therapies if they reasonably believe the treatment may benefit the patient, the patient gives informed consent, and the therapy is not expressly prohibited by law. It further bars retaliation by licensing boards, employers, or insurers for exercising these rights, while clarifying that the bill does not require insurers, hospitals, or employers to cover or provide non-standard treatments and does not override private contracts unless they conflict with the chapter. Providers harmed by a violation may sue for injunctive relief, reinstatement, damages, or other remedies, and courts are directed to give deference to free-speech rights and the evolving nature of medical science.
HB 1117 would add a new statutory chapter, RSA 332-O, and would affect the authority of licensing boards, employers, insurers, and other government agencies to discipline health care providers for discussing or using innovative or off-label treatments. It would create an express legal defense and cause of action for providers who claim retaliation or sanction based on protected communications or treatment decisions, while leaving intact existing laws that prohibit unlawful treatments and preserving private coverage and contractual arrangements. The bill is prospective only, applies to conduct on or after its effective date, and would take effect 60 days after passage.
The bill’s stated purpose and findings frame it positively, emphasizing medical innovation, patient choice, professional judgment, and First Amendment protections. The available context shows no recorded committee transcript or vote history, so there is no documented floor or committee debate to indicate formal support or opposition. Based on the text alone, the bill appears designed to appeal to advocates of medical freedom and innovation, while also attempting to reassure opponents by limiting protection to good-faith, non-misleading communications and therapies not expressly prohibited by law.
The main points of potential contention are the bill’s protection of off-label and non-standard treatments, its limitation on disciplinary authority, and its creation of a private right of action against boards, employers, insurers, or agencies. Supporters are likely to argue that the bill protects physician speech, encourages innovation, and prevents punishment for evidence-based but non-consensus care. Critics may be concerned that it could weaken professional oversight, complicate enforcement of standards of care, or encourage promotion of therapies that are not yet widely accepted, even though the bill requires good faith, informed consent, and compliance with existing law.